These transcription factors, and ZEB1 especially, have been previously shown by our laboratory as playing a central role in melanoma cell plasticity acquisition and driving both outcomes and therapy resistance in cutaneous melanoma patients [16,17,18]. The gene discussed is ZEB1; the disease is cutaneous melanoma.